Tascenso ODT® (fingolimod) – Expanded indication, new strength
December 9, 2022 - The FDA approved Cycle Pharmaceuticals’ Tascenso ODT (fingolimod), for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older.
Top